H. Endoh

Cancer Research · 2004–2006

A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from H. Endoh's perspective

Ordered by how strongly the researchers H. Endoh trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
  2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
  3. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (PLoS Medicine)
  4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  5. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. (Genes & Development)
  6. Identification of Novel Genes Coding for Small Expressed RNAs (Science)
  7. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (Journal of the American Medical Association (JAMA))
  8. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. (Molecules and Cells)
  9. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA (Nature)
  10. Fragile X-related protein and VIG associate with the RNA interference machinery. (Genes & Development)

Their papers